Interventions to address chronic disease and HIV: Strategies to promote smoking cessation among HIV-infected individuals

Current HIV/AIDS Reports

Volumn 9, Issue 4, 2012, Pages 375-384

  Niaura, Raymond ^a   Chander, Geetanjali ^b   Hutton, Heidi ^c   Stanton, Cassandra ^c  

^a Schroeder Institute for Tobacco Research and Policy Studies at Legacy   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Adaptive treatment strategy; Behavioral aspects of HIV AIDS; Bupropion; Cigarette smoking; HIV AIDS; People living with HIV AIDS (PLWHA); Smoking cessation; Tobacco; Treatment; Varenicline

Indexed keywords

AMFEBUTAMONE; NICOTINE PATCH; VARENICLINE;

ABNORMAL DREAMING; ARTICLE; BEHAVIOR THERAPY; CHRONIC DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GROUP THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIMBIC SYSTEM; MENTAL INSTABILITY; META ANALYSIS (TOPIC); NAUSEA; NICOTINE REPLACEMENT THERAPY; NUCLEUS ACCUMBENS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP DISORDER; SMOKING CESSATION; SOCIAL PSYCHOLOGY; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CARDIOVASCULAR DISEASES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PROMOTION; HIV SEROPOSITIVITY; HUMANS; MALE; MEDICATION ADHERENCE; SMOKING; SMOKING CESSATION; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84872181937     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0138-4     Document Type: Article

References (93)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238.
2. Burkhalter JE, Springer CM, Chhabra R, Ostroff JS, Rapkin BD. Tobacco use and readiness to quit smoking in low-income HIVinfected persons. Nicotine Tob Res. 2005;7:511-22. (Pubitemid 41600909)
3. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824-35.
4. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin Infect Dis. 2000;31:808-12. (Pubitemid 32295508)
5. Benard A, Bonnet F, Tessier JF, Fossoux H, Dupon M, Mercie P, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine cohort. AIDS Patient Care STDS. 2007;21:458-68. (Pubitemid 47221641)
6. Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Betancourt RM, Stein M, Tashima K, et al. HIV-positive smokers considering quitting: differences by race/ethnicity. Am J Health Behav. 2008; 32:3.
7. Rahmanian S, Wewers ME, Koletar S, Reynolds N, Ferketich A, Diaz P. Cigarette smoking in the HIV-infected population. Proc Am Thorac Soc. 2011;8:313-9.
8. Gritz ER, Vidrine DJ, Lazev AB, Amick BCI, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004;6:71-7. (Pubitemid 38372476)
9. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep. 2012;9 (3):223-30. A comprehensive review of the health consequences of smoking in HIV-infected patients.
10. Kohli R, Lo Y, Homel P, Flanigan TP, Gardner LI, Howard AA, et al. Bacterial pneumonia, HIV therapy, and disease progressionamong HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43(1):90-8. (Pubitemid 43939081)
11. Patel N, Talwar A, Reichert VC, Brady T, Jain M, Kaplan MH. Tobacco and HIV. Clin Occup Environ Med. 2006;5:193.
12. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med. 2004;164:2206.
13. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC, Veterans Aging Cohort 5 Project Team. Increased COPD among HIV-positive compared with HIV-negative veterans. Chest. 2006;130:1326-33. (Pubitemid 44786723)
14. Crothers K, Griffith TA, McGinnis KA, Rodriguez-Barradas MC, Leaf DA, Weissman S, et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20:1142-5. (Pubitemid 43110266)
15. Crothers K, Tindle HA. Prevention of bacterial pneumonia in HIV infection: focus on smoking cessation. Expert Rev Anti Infect Ther. 2011;9:759-62.
16. Cockerham L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53:102-6.
17. Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100(10):1896-903.
18. Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, et al. Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Med. 2011;12(7):412-21.
19. Piper ME, Kenford S, Fiore MC, Baker TB. Smoking cessation and quality of life: changes in life satisfaction over 3 years following a quit attempt. Ann Behav Med. 2011;43(2):262-70.
20. Vidrine DJ, Arduino RC, Gritz ER. The effects of smoking abstinence on symptom burden and quality of life among persons living with HIV/AIDS. AIDS Patient Care STDS. 2007;21:659-66. (Pubitemid 47525389)
21. Flicker L. Modifiable lifestyle risk factors for Alzheimer's disease. J Alzheimers Dis. 2010;20:803-11.
22. Lasser K, Boyd J, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606.
23. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health Report. Nicotine Tob Res. 2008;10:1691-715.
24. McClave AK, McKnight-Eily LR, Davis SP, Dube SR. Smoking characteristics of adults with selected lifetime mental illnesses: results from the 2007 National Health Interview Survey. Am J Public Health. 2010;100:2464-72.
25. Feldman JG, Minkoff H, Schneider MF, Gange SJ, Cohen M, Watts H, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from theWomen's Interagency HIV Study. Am J Public Health. 2006;96:1060-5. (Pubitemid 43825275)
26. Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10:731-6. (Pubitemid 351566558)
27. Marks King R, Vidrine DJ, Danysh HE, Fletcher FE, McCurdy S, Arduino RC, et al. Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. AIDS Patient Care STDS. 2012;26(8):479-85.
28. Reynolds NR. Cigarette smoking and HIV: more evidence for action. AIDS Educ Prev. 2009;21(3 Suppl):106-21.
29. Humfleet GL, Delucchi K, Kelley K, Hall SM, Dilley J, Harrison G. Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21 Suppl 3:54-64.
30. Cargill VA, Stone VE. HIV/AIDS: a minority health issue. Med Clin North Am. 2005;89:895-912. (Pubitemid 40755549)
31. Cox LS, Okuyemi K, Choi WS, Ahluwalia JS. A review of tobacco use treatments in U.S. ethnic minority populations. Am J Health Promot. 2011;25(5 Suppl):S11-30.
32. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service Report. Am J Prev Med. 2008;35:158-76.
33. Elzi L, Spoerl D, Voggensperger J, Nicca D, Simcock M, Bucher HC, et al. A smoking cessation program in HIV-infected individuals: a pilot study. Antivir Ther. 2006;11:787-95. (Pubitemid 44497174)
34. Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009;13:545-54.
35. Vidrine DJ, Marks RM, Arduino RC, Gritz ER. Efficacy of cell phonedelivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res. 2011;14:106-10.
36. Moadel AB, Bernstein SL, Mermelstein RJ, Arnsten JH, Dolce EH, Shuter J. A randomized controlled trial of a tailored group smoking cessation intervention for HIV-infected smokers. J Acquir Immune Defic Syndr. 2012. doi:10.1097/QAI.0b013e3182645679.
37. Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Shadel WG, Stein M, Tashima K, et al. Motivation and patch treatment for HIV + smokers: a randomized controlled trial. Addiction. 2009;104:1891-900.
38. Stanton CA, Lloyd-Richardson EE, Papandonatos GD, de Dios MA, Niaura R. Mediators of the relationship between nicotine replacement therapy and smoking abstinence among people living with HIV/AIDS. AIDS Educ Prev. 2009;21(3 Suppl):65-80.
39. Pedrol-Clotet E, Deig-Comerma E, Ribell-Bachs M, Vidal-Castell I, García-Rodríguez P. Soler A [Bupropion use for smoking cessation in hiv-infected patients receiving antiretroviral therapy]. Enferm Infecc Microbiol Clin. 2006;24:509-11. (Pubitemid 44745491)
40. Tornero C, Mafé C. Varenicline and antiretroviral therapy in patients with HIV. J Acquir Immune Defic Syndr. 2009;52:656.
41. Cui Q, Robinson L, Elston D, Smaill F, Cohen J, Quan C, et al. Safety and tolerability of varenicline tartrate (champix(®)/chantix (®)) for smoking cessation in HIV-infected subjects: a pilot openlabel study. AIDS Patient Care STDS. 2011;26(1):12-19.
42. Shuter J, Salmo LN, Shuter AD, Nivasch EC, Fazzari M, Moadel AB. Provider beliefs and practices relating to tobacco use in patients living with HIV/AIDS: a national survey. AIDS Behav. 2011;16 (2):288-94.
43. Kirshenbaum AP, Olsen DM, Bickel WK. A quantitative review of the ubiquitous relapse curve. J Subst Abuse Treat. 2009;36:8-17.
44. Hughes JR, Keely J, Naud S. Shape of the relapse curve and longterm abstinence among untreated smokers. Addiction. 2004;99:29-38. (Pubitemid 38142221)
45. Hughes JR, Peters EN, Naud S. Relapse to smoking after 1 year of abstinence: a meta-analysis. Addict Behav. 2008;33:1516-20.
46. Huber M, Ledergerber B, Jaccard R, Elzi L, Furrer H, Hirschel B, et al. Smoking prevalence, cessation rates and relapse rates in the Swiss HIV cohort study (SHCS). J Int AIDS Soc. 2010;13:1-2.
47. Hajek P, Stead LF,West R, JarvisM, Lancaster T. Relapse prevention interventions for smoking cessation. Status and date: new search for studies and content updated (conclusions changed), Published in 2009. Cochrane Database Syst Rev. 2009;21(1):CD003999.
48. Agboola S, McNeill A, Coleman T, Leonardi Bee J. A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers. Addiction. 2010;105:1362-80. A comprehensive review of behavioral and pharmacologic smoking relapse prevention treatments, along with meta-analyses.
49. Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guidedbehavioral treatments for smoking relapse prevention. J Consult Clin Psychol. 1990;58:85-92. (Pubitemid 20303455)
50. Fortmann SP, Killen JD. Nicotine gum and self-help behavioral treatment for smoking relapse prevention: results from a trial using population-based recruitment. J Consult Clin Psychol. 1995;63: 460-8.
51. Croghan IT, Hurt RD, Dakhil SR, Croghan GA, Sloan JA, Novotny PJ, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007;82:186-95.
52. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102:1292-302. (Pubitemid 47037935)
53. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med. 2001;135:423-33. (Pubitemid 32845867)
54. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. J Clin Oncol. 2003;21:914.
55. Killen JD, Fortmann SP, Murphy GM, Hayward C, Arredondo C, Cromp D, et al. Extended treatment with bupropion SR for cigarette smoking cessation. J Consult Clin Psychol. 2006;74:286-94. (Pubitemid 43807361)
56. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
57. Joseph AM, Rice K, An LC, Mohiuddin A, Lando H. Recent quitters' interest in recycling and harm reduction. Nicotine Tob Res. 2004;6:1075.
58. Fu SS, Partin MR, Snyder A, An LC, Nelson DB, Clothier B, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care. 2006;12:235-43.
59. Cupertino AP, Wick JA, Richter KP, Mussulman L, Nazir N, Ellerbeck EF. The impact of repeated cycles of pharmacotherapy on smoking cessation: a longitudinal cohort study. Arch Intern Med. 2009;169:1928-30.
60. Hughes J. An algorithm for choosing among smoking cessation treatments. J Subst Abuse Treat. 2008;34:426-32. (Pubitemid 351609297)
61. Fiore MC, Jaén CR, Baker TB, Bailey WC, Benowitz N, Curry SJ, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Executive Summary. Rockville MD: US Department of Health and Human Services. Public Health Service. May 2008.
62. Niaura R, Abrams DB. Smoking cessation: progress, priorities, and prospectus. J Consult Clin Psychol. 2002;70:494.
63. Abrams DB, Orleans CT, Niaura RS, Goldstein MG, Prochaska JO, Velicer W. Integrating individual and public health perspectives for treatment of tobacco dependence under managed health care: a combined stepped-care and matching model. Ann Behav Med. 1996;18:290-304. (Pubitemid 27171952)
64. Sobell MB, Sobell LC. Stepped care as a heuristic approach to the treatment of alcohol problems. J Consult Clin Psychol. 2000;68:573.
65. Breslin FC, Sobell MB, Sobell LC, Cunningham JA, Sdao-Jarvie K, Borsoi D. Problem drinkers: evaluation of a stepped-care approach. J Subst Abuse. 1998;10:217-32. (Pubitemid 128433416)
66. Murphy SA, Lynch KG, Oslin D, McKay JR, TenHave T. Developing adaptive treatment strategies in substance abuse research. Drug Alcohol Depend. 2007;88 Suppl 2:S24-30. (Pubitemid 46541624)
67. Hughes JR, Grass JA, Pillitteri JL. Treatment resistant smokers: a pilot study of nicotine nasal spray and inhaler. J Addict Dis. 2000;19:95-100. (Pubitemid 30649835)
68. Tønnesen P, Nørregaard J, Säwe U, Simonsen K. Recycling with nicotine patches in smoking cessation. Addiction. 1993;88:533-9. (Pubitemid 23115922)
69. Tonnesen P, Mikkelsen K, Norregaard J, Jorgensen S. Recycling of hard-core smokers with nicotine nasal spray. Eur Respir J. 1996;9:1619.
70. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. BMJ. 1995;311:363-6.
71. Smith SS, Jorenby DE, Fiore MC, Anderson JE, Mielke MM, Beach KE, et al. Strike while the iron is hot: can stepped-care treatments resurrect relapsing smokers? J Consult Clin Psychol. 2001;69:429.
72. Gonzalez DH, Nides M, Ferry LH, Segall N, Herrero LA, Krishen A, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebocontrolled study. Clin Pharmacol Ther. 2001;69:438-44. (Pubitemid 32554549)
73. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206.
74. Lavori PW, Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med. 2008;59:443-53. (Pubitemid 351287948)
75. Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. The case for treating tobacco dependence as a chronic disease. Ann Intern Med. 2008;148:554-6. (Pubitemid 351665422)
76. Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. Arch Intern Med. 2011;171:1894-900.
77. Chakraborty B. Dynamic treatment regimes for managing chronic health conditions: a statistical perspective. Am J Public Health. 2011;101:40-5.
78. Lavori PW, Dawson R. Dynamic treatment regimes: practical design considerations. Clin Trials. 2004;1:9.
79. Chakraborty B, Murphy S, Strecher V. Inference for non-regular parameters in optimal dynamic treatment regimes. Stat Methods Med Res. 2010;19:317-43.
80. Murphy SA, Van Der Laan MJ, Robins JM. Marginal mean models for dynamic regimes. J Am Stat Assoc. 2001;96:1410-23. (Pubitemid 33695590)
81. Murphy SA. An experimental design for the development of adaptive treatment strategies. Stat Med. 2005;24:1455-81. (Pubitemid 40716347)
82. Lei H, Nahum-Shani I, Lynch K, Oslin D, Murphy SA. A "SMART" design for building individualized treatment sequences. Annu Rev Clin Psychol. 2012;8:21-48. A good review of how to conceive of, construct, and test adaptive treatment strategies.
83. Pineau J, Bellemare MG, Rush AJ, Ghizaru A, Murphy SA. Constructing evidence-based treatment strategies using methods from computer science. Drug Alcohol Depend. 2007;88 Suppl 2:S52-60. (Pubitemid 46546455)
84. Thall PF, Logothetis C, Pagliaro LC,Wen S, Brown MA, Williams D, et al. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of 4 regimens. J Natl Cancer Inst. 2007;99:1613-22.
85. Collins LM, Murphy SA, Strecher V. The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): new methods for more potent health interventions. Am J Prev Med. 2007;32(5 Suppl):S112-8. (Pubitemid 46634959)
86. Dawson R, Green AI, Drake RE, McGlashan TH, Schanzer B, Lavori PW. Developing and testing adaptive treatment strategies using substance-induced psychosis as an example. Psychopharmacol Bull. 2008;41:51-67.
87. Buyze J, Van Rompaye B, Goetghebeur E. Designing a sequentially randomized study with adherence enhancing interventions for diabetes patients. Stat Med. 2010;29:1114-26.
88. Brown CH, Ten Have TR, Jo B, Dagne G, Wyman PA, Muthén B, et al. Adaptive designs for randomized trials in public health. Annu Rev Public Health. 2009;30:1-25.
89. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2011;2:CD006103.
90. Hughes J, Stead L, Lancaster T, Rev CDS. Antidepressants for smoking cessation. CochraneDatabase Syst Rev. 2007;1:CD000031.
91. Carrozzi L, Pistelli F, Viegi G. Pharmacotherapy for smoking cessation. Ther Adv Respir Dis. 2008;2:301-17.
92. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 2010;49:799-816.
93. Ebbert JO, Croghan IT, Sood A, Schroeder DR, Hays JT, Hurt RD. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11: 234-9.